Correction: Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src

類似資料

• Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src
  著者:: Perez, Marco, 等
  出版事項: (2016)
• Src activity is modulated by oxaliplatin and correlates with outcomes after hepatectomy for metastatic colorectal cancer
  著者:: Kopetz, Scott, 等
  出版事項: (2014)
• Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer
  著者:: Parseghian, Christine M., 等
  出版事項: (2017)
• Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer
  著者:: Strickler, John H., 等
  出版事項: (2013)
• The role of PIM1/PIM2 kinases in tumors of the male reproductive system
  著者:: Jiménez-García, Manuel Pedro, 等
  出版事項: (2016)